Core Insights - IMAC Holdings has launched Ignite Proteomics LLC, a subsidiary focused on personalized cancer treatment through protein-level insights, addressing the need for improved therapy selection in breast cancer and other cancers [1][2] Group 1: Market Opportunity - The genomic testing market has not fully delivered on personalized care, as genetics reveal potential but proteins indicate current tumor behavior, positioning Ignite to disrupt the multi-billion-dollar genomic testing market [2][3] - The current clinically approved indication for Ignite's test represents a market opportunity of $600 million [2] Group 2: Product Offering - Ignite's multi-protein test measures a range of proteins in a single sample, providing a comprehensive view of tumor activity and therapy vulnerability, with several biomarkers protected by licensed patents [4][9] - The test aims to improve therapy selection by identifying drug targets that standard genomic tests may overlook, thus avoiding the trial-and-error approach in treatment [8] Group 3: Strategic Vision - Ignite Proteomics is collaborating with leading cancer centers to expand clinical evidence and integrate its test into routine care, enhancing the standard of care for breast cancer [8] - The focus on antibody-drug conjugates (ADCs) and immunotherapy reflects the need for deeper insights into tumor behavior as more complex therapies are introduced [8]
IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies